Literature DB >> 1691118

Epithelial deposition of immunoglobulin G1 and activated complement (C3b and terminal complement complex) in ulcerative colitis.

T S Halstensen1, T E Mollnes, P Garred, O Fausa, P Brandtzaeg.   

Abstract

The epithelial destruction seen in ulcerative colitis remains unexplained. Complement activation has been proposed to be involved, but no definite evidence has been available to this end. In the present study, we examined immunohistochemically ulcerative colitis lesions with monoclonal antibodies to activation neoepitopes in the complement component C3b and in the cytolytically active terminal complement complex. Colonic tissue specimens from 23 patients with ulcerative colitis were examined by indirect two-color immunofluorescence staining with monoclonal antibodies to the four human immunoglobulin G subclasses and to activated complement C3b or terminal complement complex. All except two patients had activated C3b deposited apically on the surface epithelium of involved mucosa. Immunoglobulin G1 was found on the epithelium in extensively prewashed specimens from 7 of 11 patients, and a striking colocalization of immunoglobulin G1, C3b, and terminal complement complex was observed in 4. Immune deposits were not observed in 31 noninflamed specimens from the same ulcerative colitis patients. Only 1 of 44 histologically normal mucosae from 17 controls and 1 of 10 colonic adenomas contained some epithelial complement deposits. It is concluded that activated complement is often deposited along the brush border of the surface epithelium in active ulcerative colitis lesions and may be associated with immunoglobulin G1 autoantibody.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1691118     DOI: 10.1016/0016-5085(90)90343-y

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  39 in total

1.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

2.  IgG subclass distribution in serum and rectal mucosa of monozygotic twins with or without inflammatory bowel disease.

Authors:  L Helgeland; C Tysk; G Järnerot; K Kett; E Lindberg; D Danielsson; S N Andersen; P Brandtzaeg
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

Review 3.  Transepithelial migration of neutrophils: mechanisms and implications for acute lung injury.

Authors:  Rachel L Zemans; Sean P Colgan; Gregory P Downey
Journal:  Am J Respir Cell Mol Biol       Date:  2008-10-31       Impact factor: 6.914

4.  Serum and tissue autoantibodies to colonic epithelium in ulcerative colitis.

Authors:  K M Das
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

5.  Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody.

Authors:  A Dasgupta; A Mandal; K M Das
Journal:  Gut       Date:  1994-12       Impact factor: 23.059

Review 6.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

7.  Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract.

Authors:  A E Berstad; P Brandtzaeg
Journal:  Gut       Date:  1998-04       Impact factor: 23.059

Review 8.  Immunopathology of human inflammatory bowel disease.

Authors:  P Brandtzaeg; G Haraldsen; J Rugtveit
Journal:  Springer Semin Immunopathol       Date:  1997

9.  Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis.

Authors:  S Melgar; M M-W Yeung; A Bas; G Forsberg; O Suhr; A Oberg; S Hammarstrom; A Danielsson; M-L Hammarstrom
Journal:  Clin Exp Immunol       Date:  2003-10       Impact factor: 4.330

10.  Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives.

Authors:  L Biancone; G Monteleone; R Marasco; F Pallone
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.